Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beyond Belviq: Reinventing Arena To Focus On Phase II Candidates

Executive Summary

Dr. Amit Munshi, new CEO of Arena Pharmaceuticals, has already made several changes in the company’s focus and direction as it reduces its commitment to Belviq. He talked to Mike Ward about progress to date.

You may also be interested in...



Arena Rises With Post-Belviq Pipeline

Arena's valuation rose more than four-fold in 2017. CEO Amit Munshi discusses his plans for lead programs ralinepag and etrasimod following cost cutting and fundraising, and handing over rights to weight loss product Belviq to Eisai.

If Orexigen Disappears, Who's Left In The Obesity Market?

Orexigen, one of just five biopharma companies with an obesity product on the market, has become concerned about its ability to stay in business. Even so, the misfortune of several firms hasn't dissuaded others, including Novo Nordisk, from investing in the potentially large weight-loss market.

Deal Watch: Taking Care Of Business Before J.P. Morgan

Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC098182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel